30 November 2023 Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during late-April 2024 when we ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...